NewLimit, which plans to take its young-again cell reprogramming therapy into the clinic next year, raised a $435 million ...

The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.

Scientists Eye Breakthrough in Reversing Aging ...

NewLimit has come up with a new anti-aging breakthrough by developing a drug that can reverse the aging in human cells.

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...

Aging is a complex process that has long puzzled scientists. A recent study published in Engineering proposes a new theory called pro-aging metabolic reprogramming (PAMRP), which could change our ...

Aging is a complex process that has long puzzled scientists. A recent study published in Engineering proposes a new theory called Pro-Aging Metabolic Reprogramming (PAMRP), which could change our ...

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating ...